IP Library › Granted Patent US 10,087,143
Granted Patent B2
US 10,087,143 · App. 15/667,722 · Granted Oct 2, 2018

Pyridone amides as modulators of sodium channels

Inventors: Sara Sabina Hadida-Ruah (La Jolla, CA); Corey Anderson (San Diego, CA); Vijayalaksmi Arumugam (San Marco, CA); Iuliana Luci Asgian (San Diego, CA); Brian Richard Bear (Carlsbad, CA); Andreas P. Termin (Encinitas, CA); James Philip Johnson (San Diego, CA)
Assignee: VERTEX PHARMACEUTICALS INCORPORATED
C07D213/75A61K31/4412C07D401/12C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,087,143
App. No.
15/667,722
Granted
Oct 2, 2018
Kind
B2
Abstract

The invention relates to pyridone amide compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.

Claims (61)

1. A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, or visceral pain comprising administering an effective amount of a compound selected from the group consisting of:

2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide;

2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)benzamide;

4-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide;

2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(perfluoroethyl)benzamide; and

4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide.

2. The method of claim 1 , wherein the method comprises administering

2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide.

3. The method of claim 2 , wherein the method comprises treating or lessening the severity in a subject of neuropathic pain.

4. The method of claim 3 , wherein the neuropathic pain comprises idiopathic small-fiber neuropathy.

5. The method of claim 3 , wherein the neuropathic pain comprises post-herpetic neuralgia.

6. The method of claim 2 , wherein the method comprises treating or lessening the severity in a subject of musculoskeletal pain.

7. The method of claim 6 , wherein the musculoskeletal pain comprises osteoarthritis pain.

8. The method of claim 2 , wherein the method comprises treating or lessening the severity in a subject of acute pain.

9. The method of claim 8 , wherein the acute pain comprises acute post-operative pain.

10. The method of claim 2 , wherein the method comprises treating or lessening the severity in a subject of postsurgical pain.

11. The method of claim 2 , wherein the method comprises treating or lessening the severity in a subject of visceral pain.

12. The method of claim 1 , wherein the method comprises administering

2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)benzamide.

13. The method of claim 12 , wherein the method comprises treating or lessening the severity in a subject of neuropathic pain.

14. The method of claim 13 , wherein the neuropathic pain comprises idiopathic small-fiber neuropathy.

15. The method of claim 13 , wherein the neuropathic pain comprises post-herpetic neuralgia.

16. The method of claim 12 , wherein the method comprises treating or lessening the severity in a subject of musculoskeletal pain.

17. The method of claim 16 , wherein the musculoskeletal pain comprises osteoarthritis pain.

18. The method of claim 12 , wherein the method comprises treating or lessening the severity in a subject of acute pain.

19. The method of claim 18 , wherein the acute pain comprises acute post-operative pain.

20. The method of claim 12 , wherein the method comprises treating or lessening the severity in a subject of postsurgical pain.

21. The method of claim 12 , wherein the method comprises treating or lessening the severity in a subject of visceral pain.

22. The method of claim 1 , wherein the method comprises administering

4-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide.

23. The method of claim 22 , wherein the method comprises treating or lessening the severity in a subject of neuropathic pain.

24. The method of claim 23 , wherein the neuropathic pain comprises idiopathic small-fiber neuropathy.

25. The method of claim 23 , wherein the neuropathic pain comprises post-herpetic neuralgia.

26. The method of claim 22 , wherein the method comprises treating or lessening the severity in a subject of musculoskeletal pain.

27. The method of claim 26 , wherein the musculoskeletal pain comprises osteoarthritis pain.

28. The method of claim 22 , wherein the method comprises treating or lessening the severity in a subject of acute pain.

29. The method of claim 28 , wherein the acute pain comprises acute post-operative pain.

30. The method of claim 22 , wherein the method comprises treating or lessening the severity in a subject of postsurgical pain.

31. The method of claim 22 , wherein the method comprises treating or lessening the severity in a subject of visceral pain.

32. The method of claim 1 , wherein the method comprises administering

2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(perfluoroethyl)benzamide.

33. The method of claim 32 , wherein the method comprises treating or lessening the severity in a subject of neuropathic pain.

34. The method of claim 33 , wherein the neuropathic pain comprises idiopathic small-fiber neuropathy.

35. The method of claim 33 , wherein the neuropathic pain comprises post-herpetic neuralgia.

36. The method of claim 32 , wherein the method comprises treating or lessening the severity in a subject of musculoskeletal pain.

37. The method of claim 36 , wherein the musculoskeletal pain comprises osteoarthritis pain.

38. The method of claim 32 , wherein the method comprises treating or lessening the severity in a subject of acute pain.

39. The method of claim 38 , wherein the acute pain comprises acute post-operative pain.

40. The method of claim 32 , wherein the method comprises treating or lessening the severity in a subject of postsurgical pain.

41. The method of claim 32 , wherein the method comprises treating or lessening the severity in a subject of visceral pain.

42. The method of claim 1 , wherein the method comprises administering

4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide.

43. The method of claim 42 , wherein the method comprises treating or lessening the severity in a subject of neuropathic pain.

44. The method of claim 43 , wherein the neuropathic pain comprises idiopathic small-fiber neuropathy.

45. The method of claim 43 , wherein the neuropathic pain comprises post-herpetic neuralgia.

46. The method of claim 42 , wherein the method comprises treating or lessening the severity in a subject of musculoskeletal pain.

47. The method of claim 46 , wherein the musculoskeletal pain comprises osteoarthritis pain.

48. The method of claim 42 , wherein the method comprises treating or lessening the severity in a subject of acute pain.

49. The method of claim 48 , wherein the acute pain comprises acute post-operative pain.

50. The method of claim 42 , wherein the method comprises treating or lessening the severity in a subject of postsurgical pain.

51. The method of claim 42 , wherein the method comprises treating or lessening the severity in a subject of visceral pain.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2017
From: HADIDA-RUAH, SARA SABINA; ANDERSON, COREY; ARUMUGAM, VIJAYALAKSMI; ASGIAN, IULIANA LUCI; BEAR, BRIAN RICHARD; TERMIN, ANDREAS P.; JOHNSON, JAMES PHILIP
To: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 043188/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2017
From: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 043188/0413 →
Continuity (5)
Continuation 15174896 · Jun 6, 2016
Continuation 14699437 · Apr 29, 2015
Continuation 14167759 · Jan 29, 2014
Provisional Application 61759059 · Jan 31, 2013
Related Publication 20180016235A1 · Jan 18, 2018
Cited By (7)
US 12,247,021 US 12,258,333 US 12,281,057 US 12,440,481 US 12,441,703 US 12,503,439 US 12,662,470